# Empagliflozin in Renal Transplant Recipients

> **NCT03157414** · PHASE4 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 49 (actual)

## Conditions studied

- Diabetes Mellitus
- Renal Insufficiency
- Safety Issues

## Interventions

- **DRUG:** Empagliflozin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03157414
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-07
- **Primary completion:** 2018-06-28
- **Final completion:** 2018-06-28
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03157414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03157414, "Empagliflozin in Renal Transplant Recipients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03157414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*